Used in the treatment of hypercholesterolemia and other lipid disorders by targeting and inhibiting PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein (LDL) cholesterol from the blood. By blocking PCSK9, this antibody increases the number of LDL receptors on liver cells, leading to significantly lower levels of circulating LDL cholesterol. It is particularly effective in patients with familial hypercholesterolemia or those who cannot achieve target cholesterol levels with statins alone. Administered via subcutaneous injection, it offers a long-acting option for cardiovascular risk reduction in high-risk patients.